| Autor: |
Sharma, Satish, Apurva A Patel, Aruj Dhyani, Nikesh Aggarwal, Yuganshi Gupta, Goutham R Reddy, Debajyoti Maji, Harshvardhan A, Kuttikat, Phillip G, Ananya Pareek, Parikh, Sonia, Harsha P Panchal |
| Jazyk: |
angličtina |
| Rok vydání: |
2022 |
| Předmět: |
|
| DOI: |
10.5281/zenodo.6390144 |
| Popis: |
Treatment of multi-resistant ovarian cancer is palliative. Patient after receiving multiple lines of chemotherapy are neither in good PS nor have good compliance to receive further toxic treatment. Bevacizumab is a vascular endothelial growth factor which inhibit angiogenesis. Bevacizumab is generally used in combination with chemotherapy. Due to its low toxicity profile, improvement in progression free survival (PFS), easy availability in resources limited settings, it is a good adjunct to more toxic and costly regimens. Development of hypertension is one of the most common adverse event of bevacizumab. We present a case of patient of metastatic carcinoma ovary, who developed grade 4 hypertension post 1st cycle of bevacizumab for which treatment was withheld. After control of blood pressure, she was rechallenged with bevacizumab and patient did not had any hypertensive episode and is doing well at present. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
